Physician profile
Robert W Greer
NPI 1508862822
$5,184.79
in general payments reported to CMS, 2019-2025
29 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $620 · 2021: $636 · 2022: $617 · 2023: $729 · 2024: $711 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $683.69 | 2019-2024 | Xarelto |
| Pfizer INC. | $650.80 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $619.84 | 2019-2025 | |
| Amgen INC. | $592.66 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $392.75 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $234.67 | 2024 | Pascal |
| Astrazeneca Pharmaceuticals Lp | $210.70 | 2019-2023 | Farxiga |
| Abiomed | $203.17 | 2019-2025 | Impella |
| Merck Sharp & Dohme LLC | $191.18 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $178.81 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $130.26 | 2021-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $129.62 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $129.26 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.51 | 2022-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $98.98 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $90.93 | 2019-2022 | |
| Biotronik INC. | $87.46 | 2022-2025 | Acticor 7 Vr-T Dx |
| Boston Scientific Corporation | $67.62 | 2020-2025 | Watchman Flx |
| Atricure, INC. | $60.92 | 2025 | Synergy Ablation System |
| Gilead Sciences, INC. | $43.79 | 2019 | |
| Baxter Healthcare | $43.21 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Arbor Pharmaceuticals, INC. | $41.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.44 | 2021 | |
| Medtronic Vascular, INC. | $32.12 | 2019 | |
| Medtronic, INC. | $28.17 | 2022 | |
| Philips North America LLC | $24.71 | 2024 | (Ck4) Mcot |
| Abbott Laboratories | $22.99 | 2023 | Cardiomems |
| Irhythm Technologies, INC. | $22.01 | 2023 | Zio Xt Patch |
| Scpharmaceuticals INC. | $16.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.